Genetic Technologies Ltd (GENE) 0.82 $GENE
Why Genetic Technologies (GENE) Stock Is Spiking Today
at The Street - Mon Jul 07, 1:31PM CDT
Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.
Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014
Marketwire - Mon Jul 07, 4:30AM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the number of BREVAGen(TM) test samples received during the quarter ended June 30, 2014 returned to levels achieved in late CY13. Total patient samples received during the quarter were 1,096, representing 37% growth over the March 2014 quarter (800 samples).
Genetic Technologies Announces Appointment of Chief Financial Officer
Marketwire - Wed May 28, 9:52PM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce the appointment of Mr Eutillio Buccilli to the role of Chief Financial Officer, effective 2 June 2014.
Genetic Technologies Executes Agreement With Promega Corporation
Marketwire - Mon Mar 24, 11:48AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) announced today that in compliance with the ASX Continuous Disclosure Rules, the company is pleased to report the execution of a Settlement, Covenant and License Agreement with Promega Corporation, which has a principal place of business in Madison, Wisconsin, USA.
5 Stocks Ready for Breakouts
at The Street - Fri Mar 21, 12:48PM CDT
These stocks look poised to break out and trade higher from current levels.
Genetic Technologies Announces Publication of Economic Modeling Study Supporting Cost-Effectiveness of BREVAGen(TM) to Direct Tamoxifen Chemoprevention
Marketwire - Fri Mar 07, 4:15AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced the recent online publication in the journal Applied Health Economics and Health Policy of a study entitled, "Economic Evaluation of Using a Genetic Test to Direct Breast Cancer Chemoprevention in White Women With a Previous Breast Biopsy." This study was a collaborative project between Genetic Technologies Limited and Archimedes Inc. of San Francisco, a healthcare modeling and analytics organization. The study examined the cost-effectiveness of utilizing BREVAGen to direct tamoxifen chemoprevention.
Genetic Technologies Provides Further Update on Corporate Structure
Marketwire - Mon Feb 24, 10:22AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to advise that Ms. Alison Mew has confirmed that she will return to full-time work to resume her position as the Company's Chief Executive Officer as of Tuesday, 1 April 2014.
Genetic Technologies Announces Update on Intellectual Property
Marketwire - Wed Feb 12, 11:26AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that it received a further ExParte Re-Examination Certificate from the United States Patent and Trademark Office ("USPTO"
, dated February 10, 2014 (the "Certificate" . The Certificate follows the third request for ex parte re-examination of claims 1-15, 17,18, 26-29 and 32 of the Company's U.S. Patent No. 5,612,179 (the '179 patent) by Merial L.L.C. of Duluth, Georgia, as announced by the Company on September 30, 2013.
Genetic Technologies Provides Corporate and Financial Update for Quarter Ended December 31, 2013
Marketwire - Thu Jan 30, 9:43AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE)
Genetic Technologies Announces New Record Growth in Number of BREVAGen(TM) Tests Received for December Quarter
Marketwire - Wed Jan 08, 4:15AM CST
Genetic Technologies Limited (NASDAQ: GENE) (ASX: GTG) today announced that a new record number of BREVAGen(TM) test samples were received during the quarter ended December 31, 2013. Total patient samples received during the quarter was 1,125, representing growth of more than 23% over the preceding September quarter and demonstrating a continuation of the significant increase trend in market traction.
Genetic Technologies Announces Issue of Redeemable Convertible Note and Receipt of Funds
Marketwire - Mon Dec 23, 8:07AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that the Redeemable Convertible Note (the "Note" described in the Company's ASX announcement dated September 10, 2013, which was subsequently approved by the Company's shareholders at an Extraordinary General Meeting on November 29, 2013, has now been issued.
Genetic Technologies Announces Share Reduction Schedule With Major Shareholder
Marketwire - Wed Dec 18, 12:58PM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that entities associated with the Company's founder and largest shareholder, Dr. Mervyn Jacobson (collectively, the "Jacobson Entities" , have entered into several transactions which will result in the disposal of 105,937,500 shares in the Company. As a result, Dr. Jacobson's beneficial interest in the issued capital of the Company will be reduced from 23.83% to 6.15%.
PEARL W. YEE, M.D. INC. OF SAN FRANCISCO ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
GlobeNewswire - Mon Sep 16, 9:08AM CDT
Pearl Yee, MD, FACOG and clinical professor at the University of California, San Francisco, is pleased to announce that her private practice, Pearl W. Yee, M.D. Inc, in San Francisco is now offering the BREVAGen(TM) predictive risk test. Clinically validated, BREVAGen is the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer.
Genetic Technologies Receives Certification for New York State
Marketwire - Fri Aug 30, 6:00AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that it has received its Clinical Laboratory Permit from the New York State Department of Health ("DoH" . In late July, the Company's Melbourne laboratories were inspected under New York's DoH Clinical Laboratory Evaluation Program ("CLEP" and, following the two-day audit, it subsequently received a Laboratory Evaluation Report with "No significant deficiencies". Thus, the permit was able to be issued immediately.
OB/GYN ASSOCIATES IN LEWISBURG, PA ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
GlobeNewswire - Mon Aug 26, 12:06PM CDT
Russell Stankiewicz, MD, FACOG, CCD, NMCP, is pleased to announce that OB/GYN Associates of Lewisburg, P.C. in Lewisburg, PA is now offering the BREVAGen(TM) predictive risk test. Clinically validated, BREVAGen is the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer.
Genetic Technologies Announces Financing and Intended Use of Proceeds
Marketwire - Thu Aug 01, 4:15AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE)
Genetic Technologies Announces U.S. Patent Office Allows First Patent for ImmunAid
Marketwire - Wed Jul 10, 4:15AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that ImmunAid Limited, in which GTG holds a 45% direct equity interest and is currently the largest shareholder, has just been advised that its first U.S. patent has now been formally allowed by the relevant U.S. Government authority, the United States Patent and Trademark Office.
Genetic Technologies Announces Record Number of BREVAGen(TM) Tests
Marketwire - Mon Jul 01, 6:00AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) announces that a record number of BREVAGen(TM) test samples were received during the quarter ended June 30, 2013. Total patient samples received during the quarter was 599, representing growth of more than 48% over the preceding March quarter, demonstrating a significant increasing trend in market traction.
THE HEWITT CENTER FOR BREAST WELLNESS AT GRIFFIN HOSPITAL IN DERBY, CT LAUNCHES HIGH-RISK PROGRAM INCLUDING STATE-OF-THE-ART BREAST CANCER SCREENING OPTIONS
GlobeNewswire - Mon Jun 24, 11:16AM CDT
Denise Barajas, MD, medical director at The Hewitt Center for Breast Wellness in Derby, CT, has launched a high-risk breast cancer program that includes state-of-the-art screening options including the BREVAGen(TM) predictive risk test. Clinically validated, BREVAGenis the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer.
Genetic Technologies Settles Its Dispute With Ingelheim, Germany-Based Bioscientia Institute for Medical Diagnostics
Marketwire - Mon Jun 24, 4:15AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that it has now settled its dispute with Bioscientia Institute for Medical Diagnostics, based in Ingelheim, Germany, and accordingly, the law suit filed by GTG against Bioscientia, which was reported to ASX on March 19, 2013, will now be withdrawn.
Why Genetic Technologies (GENE) Stock Is Spiking Today
at The Street - Mon Jul 07, 1:31PM CDT
Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.
Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014
Marketwire - Mon Jul 07, 4:30AM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the number of BREVAGen(TM) test samples received during the quarter ended June 30, 2014 returned to levels achieved in late CY13. Total patient samples received during the quarter were 1,096, representing 37% growth over the March 2014 quarter (800 samples).
Genetic Technologies Announces Appointment of Chief Financial Officer
Marketwire - Wed May 28, 9:52PM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce the appointment of Mr Eutillio Buccilli to the role of Chief Financial Officer, effective 2 June 2014.
Genetic Technologies Executes Agreement With Promega Corporation
Marketwire - Mon Mar 24, 11:48AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) announced today that in compliance with the ASX Continuous Disclosure Rules, the company is pleased to report the execution of a Settlement, Covenant and License Agreement with Promega Corporation, which has a principal place of business in Madison, Wisconsin, USA.
5 Stocks Ready for Breakouts
at The Street - Fri Mar 21, 12:48PM CDT
These stocks look poised to break out and trade higher from current levels.
Genetic Technologies Announces Publication of Economic Modeling Study Supporting Cost-Effectiveness of BREVAGen(TM) to Direct Tamoxifen Chemoprevention
Marketwire - Fri Mar 07, 4:15AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced the recent online publication in the journal Applied Health Economics and Health Policy of a study entitled, "Economic Evaluation of Using a Genetic Test to Direct Breast Cancer Chemoprevention in White Women With a Previous Breast Biopsy." This study was a collaborative project between Genetic Technologies Limited and Archimedes Inc. of San Francisco, a healthcare modeling and analytics organization. The study examined the cost-effectiveness of utilizing BREVAGen to direct tamoxifen chemoprevention.
Genetic Technologies Provides Further Update on Corporate Structure
Marketwire - Mon Feb 24, 10:22AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to advise that Ms. Alison Mew has confirmed that she will return to full-time work to resume her position as the Company's Chief Executive Officer as of Tuesday, 1 April 2014.
Genetic Technologies Announces Update on Intellectual Property
Marketwire - Wed Feb 12, 11:26AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that it received a further ExParte Re-Examination Certificate from the United States Patent and Trademark Office ("USPTO"
, dated February 10, 2014 (the "Certificate" . The Certificate follows the third request for ex parte re-examination of claims 1-15, 17,18, 26-29 and 32 of the Company's U.S. Patent No. 5,612,179 (the '179 patent) by Merial L.L.C. of Duluth, Georgia, as announced by the Company on September 30, 2013. Genetic Technologies Provides Corporate and Financial Update for Quarter Ended December 31, 2013
Marketwire - Thu Jan 30, 9:43AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE)
Genetic Technologies Announces New Record Growth in Number of BREVAGen(TM) Tests Received for December Quarter
Marketwire - Wed Jan 08, 4:15AM CST
Genetic Technologies Limited (NASDAQ: GENE) (ASX: GTG) today announced that a new record number of BREVAGen(TM) test samples were received during the quarter ended December 31, 2013. Total patient samples received during the quarter was 1,125, representing growth of more than 23% over the preceding September quarter and demonstrating a continuation of the significant increase trend in market traction.
Genetic Technologies Announces Issue of Redeemable Convertible Note and Receipt of Funds
Marketwire - Mon Dec 23, 8:07AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that the Redeemable Convertible Note (the "Note"
described in the Company's ASX announcement dated September 10, 2013, which was subsequently approved by the Company's shareholders at an Extraordinary General Meeting on November 29, 2013, has now been issued. Genetic Technologies Announces Share Reduction Schedule With Major Shareholder
Marketwire - Wed Dec 18, 12:58PM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that entities associated with the Company's founder and largest shareholder, Dr. Mervyn Jacobson (collectively, the "Jacobson Entities"
, have entered into several transactions which will result in the disposal of 105,937,500 shares in the Company. As a result, Dr. Jacobson's beneficial interest in the issued capital of the Company will be reduced from 23.83% to 6.15%. PEARL W. YEE, M.D. INC. OF SAN FRANCISCO ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
GlobeNewswire - Mon Sep 16, 9:08AM CDT
Pearl Yee, MD, FACOG and clinical professor at the University of California, San Francisco, is pleased to announce that her private practice, Pearl W. Yee, M.D. Inc, in San Francisco is now offering the BREVAGen(TM) predictive risk test. Clinically validated, BREVAGen is the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer.
Genetic Technologies Receives Certification for New York State
Marketwire - Fri Aug 30, 6:00AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that it has received its Clinical Laboratory Permit from the New York State Department of Health ("DoH"
. In late July, the Company's Melbourne laboratories were inspected under New York's DoH Clinical Laboratory Evaluation Program ("CLEP" and, following the two-day audit, it subsequently received a Laboratory Evaluation Report with "No significant deficiencies". Thus, the permit was able to be issued immediately. OB/GYN ASSOCIATES IN LEWISBURG, PA ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
GlobeNewswire - Mon Aug 26, 12:06PM CDT
Russell Stankiewicz, MD, FACOG, CCD, NMCP, is pleased to announce that OB/GYN Associates of Lewisburg, P.C. in Lewisburg, PA is now offering the BREVAGen(TM) predictive risk test. Clinically validated, BREVAGen is the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer.
Genetic Technologies Announces Financing and Intended Use of Proceeds
Marketwire - Thu Aug 01, 4:15AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE)
Genetic Technologies Announces U.S. Patent Office Allows First Patent for ImmunAid
Marketwire - Wed Jul 10, 4:15AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that ImmunAid Limited, in which GTG holds a 45% direct equity interest and is currently the largest shareholder, has just been advised that its first U.S. patent has now been formally allowed by the relevant U.S. Government authority, the United States Patent and Trademark Office.
Genetic Technologies Announces Record Number of BREVAGen(TM) Tests
Marketwire - Mon Jul 01, 6:00AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) announces that a record number of BREVAGen(TM) test samples were received during the quarter ended June 30, 2013. Total patient samples received during the quarter was 599, representing growth of more than 48% over the preceding March quarter, demonstrating a significant increasing trend in market traction.
THE HEWITT CENTER FOR BREAST WELLNESS AT GRIFFIN HOSPITAL IN DERBY, CT LAUNCHES HIGH-RISK PROGRAM INCLUDING STATE-OF-THE-ART BREAST CANCER SCREENING OPTIONS
GlobeNewswire - Mon Jun 24, 11:16AM CDT
Denise Barajas, MD, medical director at The Hewitt Center for Breast Wellness in Derby, CT, has launched a high-risk breast cancer program that includes state-of-the-art screening options including the BREVAGen(TM) predictive risk test. Clinically validated, BREVAGenis the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer.
Genetic Technologies Settles Its Dispute With Ingelheim, Germany-Based Bioscientia Institute for Medical Diagnostics
Marketwire - Mon Jun 24, 4:15AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that it has now settled its dispute with Bioscientia Institute for Medical Diagnostics, based in Ingelheim, Germany, and accordingly, the law suit filed by GTG against Bioscientia, which was reported to ASX on March 19, 2013, will now be withdrawn.
